Learning Hub

• Typically 2–50 amino acids long — smaller than a protein, larger than a single amino acid
• Occur naturally throughout the body as signalling molecules
• Studied for roles in tissue repair, hormone pathways, and cellular metabolism

A peptide is a short chain of amino acids joined by peptide bonds. Where a protein might run to hundreds or thousands of residues folded into a complex three-dimensional shape, a peptide is short enough that its sequence largely determines what it does. That compactness is exactly why peptides are interesting to researchers: a defined sequence, a defined mass, and a defined interaction with its target.

The body makes thousands of them. Insulin is a peptide. So are oxytocin, glucagon, and the growth-hormone-releasing hormones. They act as messengers — binding a receptor on a cell surface and instructing that cell to start, stop, or modulate a process. Nothing about a peptide forces an outcome; it delivers a signal that existing biological machinery then acts on.

Research-grade peptides are produced by solid-phase synthesis, purified by high-performance liquid chromatography (HPLC), and supplied as a lyophilized (freeze-dried) white powder in a sealed vial. Purity and identity are confirmed by HPLC and mass spectrometry, and reported on a certificate of analysis for the specific lot.

• Bind specific receptors rather than acting broadly across tissues
• Modulate existing pathways instead of introducing new ones
• Short half-lives — most are cleared quickly and do not accumulate

Most peptides studied today are receptor agonists: their sequence is shaped so that it fits a particular receptor, and binding it triggers a cascade inside the cell. Because the fit is specific, effects tend to be concentrated in the tissues that express that receptor — which is what distinguishes a peptide from a compound that acts on the whole system at once.

Three families come up repeatedly in the literature. Repair peptides such as BPC-157 and TB-500 are studied for their effect on angiogenesis and fibroblast migration — the processes behind wound and soft-tissue healing. Secretagogues such as CJC-1295 and Ipamorelin act upstream of growth hormone, prompting the pituitary to release its own rather than supplying it externally. Metabolic peptides such as the incretin analogues act on receptors involved in glucose handling and appetite signalling.

Peptides are also fragile. Peptide bonds are readily cleaved by proteases, so most have half-lives measured in minutes to hours, and oral delivery is generally ineffective because the digestive tract degrades them before absorption. This is why so much peptide research concerns delivery and stabilisation as much as the sequences themselves.

• Keep lyophilized vials frozen or refrigerated and shielded from light
• Reconstitute with bacteriostatic water; refrigerate afterwards
• Every lot ships with a certificate of analysis you can check yourself

Lyophilized peptide is stable for a long time when it is kept cold and dry. Store unopened vials in a freezer where possible, or refrigerated, away from light and humidity. Once a vial is reconstituted the clock starts: keep it refrigerated, avoid shaking it, and observe the window noted on that lot's certificate of analysis.

Bacteriostatic water — sterile water containing roughly 0.9% benzyl alcohol — is the usual reconstitution solvent because the preservative inhibits bacterial growth in a vial that will be accessed more than once. Direct the stream against the vial wall rather than onto the powder, and let it dissolve rather than agitating it.

On legal status: the compounds sold here are supplied strictly for laboratory and analytical research. They are not approved by the FDA or any comparable authority for human or veterinary use, and nothing in this hub should be read as medical, dosing, or legal advice. Regulations differ by country and by province or state — the obligation to know and follow the rules where you are sits with the purchaser.

• GHK-Cu is among the most heavily studied copper-binding peptides
• Research focuses on collagen and elastin production in dermal fibroblasts
• Epithalon is investigated for its effect on telomerase activity

Skin ageing is, at the tissue level, a decline in the extracellular matrix: less collagen, less elastin, slower turnover, and a fibroblast population that responds less readily to injury. Several peptides are studied precisely because they appear to intervene at that level rather than at the surface.

GHK-Cu — a copper-binding tripeptide first isolated from human plasma — is the most documented of them. The published literature examines its effect on collagen and glycosaminoglycan synthesis, antioxidant activity, and gene expression associated with tissue remodelling. Epithalon, a synthetic tetrapeptide, is studied along a different axis: its reported influence on telomerase activity and pineal regulation puts it in the longevity rather than the topical-cosmetic literature.

Worth keeping in perspective: much of this work is in vitro or in animal models, and the results that hold up in a dish do not always translate. The interesting question in this area is not whether a peptide can raise collagen expression in cultured fibroblasts — several can — but what happens in intact tissue over time.

• Semax and Selank originate from Russian clinical research programmes
• Research centres on BDNF expression and neurotransmitter modulation
• Blood-brain barrier penetration is the central delivery problem

Nootropic peptide research is dominated by a small number of sequences with an unusual history. Semax, a fragment analogue of ACTH(4-10), and Selank, derived from the immunopeptide tuftsin, were both developed in Russia and have a domestic clinical literature that is far larger than their profile in English-language journals would suggest.

The mechanisms proposed for them differ. Semax research concentrates on brain-derived neurotrophic factor (BDNF) and nerve growth factor expression, and on dopaminergic and serotonergic modulation. Selank is studied more for its effect on GABAergic signalling and on the expression of genes linked to anxiety. Neither is well characterised by the standards applied to approved neurological drugs, and independent replication outside their originating institutions remains thin.

The hard constraint on all of this is delivery. The blood-brain barrier excludes most peptides by design, and the ones that reach the central nervous system in meaningful quantity tend to be small, lipophilic, or actively transported. A great deal of the published work in this area is really about getting the molecule to the tissue rather than about what it does once it arrives.

• BPC-157 and TB-500 dominate the soft-tissue repair literature
• Growth-hormone secretagogues act on the pituitary rather than supplying GH
• Most peptides are prohibited in competition under WADA rules

Two peptides account for most of the recovery research. BPC-157, a synthetic fragment of a protein found in gastric juice, is studied for angiogenesis and for tendon, ligament, and gut healing in animal models. TB-500, a synthetic version of the active region of thymosin beta-4, is examined for actin regulation and cell migration — the mechanical side of how a wound closes.

Growth-hormone secretagogues sit in a different category. CJC-1295, Ipamorelin, and Tesamorelin do not supply growth hormone; they prompt the pituitary to release more of its own, which preserves the natural pulsatile release pattern. The research interest lies in whether that distinction matters physiologically — and in the differing selectivity of each compound, since some secretagogues also raise cortisol and prolactin while others largely do not.

One practical note for anyone competing: the World Anti-Doping Agency prohibits growth-hormone secretagogues and most of the peptides discussed here, both in and out of competition. BPC-157 was added to the prohibited list in 2022. Nothing sold on this site is intended for human use, and anyone subject to anti-doping testing should treat that list as the operative reference.